Daxotel Injection 20
Product Code: 1
Pack Size: 1 Vial
- Price: $30.48 ৳0 ,
Each vial contains Docetaxel Anhydrous USP 20mg/ml.
Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with Doxorubicin and Cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. Non-small Cell Lung Cancer (NSCLC): Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel in combination with Cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. Castration-Resistant Prostate Cancer (CRPC): Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. Gastric Adenocarcinoma (GC): Docetaxel in combination with Cisplatin and Fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. Squamous Cell Carcinoma of the Head and Neck (SCCHN): Docetaxel in combination with Cisplatin & Fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head & neck (SCCHN).
Major Ingredients
Each vial contains Docetaxel Anhydrous USP 20mg/ml.
Major Functionality
Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel in combination with Doxorubicin and Cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. Non-small Cell Lung Cancer (NSCLC): Docetaxel as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel in combination with Cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. Castration-Resistant Prostate Cancer (CRPC): Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. Gastric Adenocarcinoma (GC): Docetaxel in combination with Cisplatin and Fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. Squamous Cell Carcinoma of the Head and Neck (SCCHN): Docetaxel in combination with Cisplatin & Fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head & neck (SCCHN).
Manufacture Information
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.
_1694337890.jpg)
